Join
Live feed
·
PRReleasevia Quantisnow
Gyre Therapeutics Inc. logo

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

ByQuantisnow·Wall Street's wire, on your screen.
GYRE· Gyre Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GYRE (Gyre Therapeutics Inc.) and more on Quantisnow.